[Studies on the immune state evaluated by various skin antigens in patients with cervical cancer (author's transl)].
Cutaneous delayed hypersensitivity (CDH) tests, using 6 antigens (PHA, PPD, SK-SD, Candida, Mumps and DNCB) were performed in 260 patients with cervical cancer and the following results were obtained. 1) Decrease in incidence of positive CDH (PHA, PPD and DNCB) was found as the clinical stage advanced. Especially, decrease in incidence of positive CDH (DNCB and PHA) was found in stage III and IV. 2) There was no relationship between the incidence of positive CDH (SK-SD, Candida and Mumps) and clinical stage but, decrease in incidence of these tests was found in stage III and IV. 3) In comparison on numbers of positive CDH, there was no significance in control groups and cervical cancer patients. 4) Incidence of advanced invasion of primary lesion (gamma and delta type) was 83.7% in DNCB-negative group who were treated with curative operation. 5) Incidence of regional lymph node metastasis was 42.9% in Candida-negative group, whereas, 16.2% in Candida-positive group who were treated with curative operation.
D000941:Antigens / Q000008:administration & dosage*; D000946:Antigens, Fungal / Q000008:administration & dosage; D002175:Candida / Q000276:immunology; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D008207:Lymphatic Metastasis; D010835:Phytohemagglutinins; D012882:Skin Tests; D002583:Uterine Cervical Neoplasms / Q000276:immunology*
D000941:Antigens; D000946:Antigens, Fungal; D010835:Phytohemagglutinins